

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



绿竹生物
LUZHU BIOTECH

Beijing Luzhu Biotechnology Co., Ltd.

北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2480)

VOLUNTARY ANNOUNCEMENT SUCCESSFUL COMPLETION OF PHASE I CLINICAL TRIAL OF LZ901 IN THE U.S.

This announcement is made by Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business updates of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the phase I clinical trial of LZ901 in the United States of America (the “**U.S.**”) has been completed successfully in September 2025. According to the results of the clinical trial, both the high-dose group and low-dose group of the LZ901 vaccine demonstrated good safety and immunogenicity portfolio as compared to the placebo group, laying a foundation for subsequent clinical study.

ABOUT THE PHASE I CLINICAL TRIAL IN THE U.S.

The phase I clinical trial of LZ901 in the U.S. was initiated in February 2023, and is a randomized, double-blind, placebo-controlled and dose escalation study for evaluating the safety and tolerability of LZ901 in healthy subjects aged 50 to 70 years inclusive. A total of 66 subjects were enrolled in the phase I clinical trial of LZ901 in the U.S..

According to the results of the phase I clinical trial of LZ901 in the U.S., both the high-dose group and low-dose group of the LZ901 vaccine demonstrated good safety and immunogenicity portfolio as compared to the placebo group. The primary research objective of this clinical trial is to verify the safety of the vaccine and only the low-dose group of the LZ901 vaccine experienced vaccine-related mild adverse reactions (4.35%), while no vaccine-related adverse reactions were observed in the high-dose group of the LZ901 vaccine or the placebo group.

ABOUT LZ901

LZ901 is a recombinant herpes zoster vaccine candidate independently developed by the Group, and is the core product of the Group. LZ901 aims to prevent the occurrence of herpes zoster and related complications caused by herpes zoster, including postherpetic neuralgia for adults aged 40 years and above. The phase III clinical trial of LZ901 in the People's Republic of China (the “**PRC**”) has met the pre-defined clinical objectives and achieved expected clinical outcomes. As of the date of this announcement, the biologics license application for LZ901 has been accepted and is currently being assessed by the National Medical Products Administration of the PRC.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that LZ901 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, October 9, 2025

As at the date of this announcement, the Board comprises Mr. KONG Jian, Ms. PENG Ling and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Ms. HOU Aijun, Mr. LEUNG Wai Yip and Mr. LIANG Yeshe as independent non-executive Directors.